Underresearched and often dismissed, migraines have made their sufferers a resourceful bunch. But a promising new drug might finally offer relief.
To be clear: A migraine is not a headache, and people with migraines don’t like their condition to be called one. It’s not that headaches aren’t a part of a migraine: They are. But a headache is a single symptom of a multifaceted neurological disease— one that includes loss of vision, nausea, and sensitivity to light, sound, and smell. And those are just the common side effects. Some sufferers find themselves yawning compulsively, slurring their speech, and losing sensation on one side of their bodies. Some migraineurs (yes, that is the technically accurate moniker for migraine sufferers) start seeing big things as small—a side effect dubbed “Alice in Wonderland syndrome” by doctors.
Nonetheless, for as long as they have existed, migraines have been trivialized as headaches, or dismissed altogether. Which is clear when you look at the treatments available: Almost every drug used between 1550 B.C. and today has been a repurposed one. Poultices of opium and honey, Botox, antidepressants—drugs whose efficacy was not intended but stumbled upon. Triptan, a class of vessel constrictors created to abort (not prevent) attacks at their onset, was released in 1991 and has been the only class of drug created specifically for migraines—that is, until now. On May 17, a preventative drug called Aimovig, 30 years in the making, gained FDA approval; it’s a monthly shot that modulates patients’ levels of CGRP, a neurotransmitter whose levels rise during migraine attacks. This means that it could be in the hands (or arms— it’s injectable) of migraineurs within the month.
Esta historia es de la edición May 28, 2018 de New York magazine.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 8500 revistas y periódicos.
Ya eres suscriptor ? Conectar
Esta historia es de la edición May 28, 2018 de New York magazine.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 8500 revistas y periódicos.
Ya eres suscriptor? Conectar
War of Attrition
In the Kendrick-vs.-Drake battle, no one wins.
More Than Mad
Grief drives a fantastic installment in George Miller's series.
We've Hit Peak Theater
Nobody knows how to succeed on Broadway anymore.
Small Plates, Big Checks
Why restaurant prices feel so high—and why they’re going to stay that way.
Nobody Wants to Mow the Lawn at the Beach
Breck and Georgia Eisner's Amagansett retreat gives the children a cottage of their own.
HOW TO CRIMINALIZE a PROTEST
In Atlanta, the George Floyd demonstrations of four years ago are being used as evidence of illegal gang activity-and the activists of today could be next.
CHESS BRAT
It was the biggest cheating scandal in chess history. Now, cleared of the most serious accusations, Hans Niemann is gunning for a world title-and doubling down on his opponent-trashing, hotel-wrecking, money-flaunting ways.
MIRIAM ADELSON'S UNFINISHED BUSINESS
One of Israel's most ardent supporters, she could transform the presidential election if she gives to Trump like she did in 2020.
ON THE CAMPAIGN TRIAL
Trump is running for president while bumping into the past at a Manhattan criminal courthouse.
Lord Maurice Saatchi
The British advertising executive is thoroughly enjoying the rollout for his new book, Orgasm.